Key result
Diabetic cardiomyopathy is a major complication of diabetes characterized by functional and structural myocardial damage, with current treatments focusing on glycemic control and delaying heart failure.
Why the study?
Diagnosing and preventing diabetic cardiomyopathy remains challenging due to atypical symptoms, necessitating a summary of current knowledge on molecular mechanisms to develop diagnostic approaches and effective drugs.
This review provides a comprehensive overview of the diagnostic modalities and underlying molecular mechanisms of diabetic cardiomyopathy to guide future therapeutic developments.
Management of diabetic cardiomyopathy remains limited to glycemic control; review extends molecular insights to guide future targeted therapies.
The incidence of diabetes mellitus has become a major public health concern due to lifestyle alterations. Moreover, the complications associated with diabetes mellitus deeply influence the quality of life of patients. Diabetic cardiomyopathy (DC) is a type of diabetes mellitus complication characterized by functional and structural damage in the myocardium but not accompanied by coronary arterial disease. Currently, diagnosing and preventing DC is still a challenge for physicians due to its atypical symptoms. For this reason, it is necessary to summarize the current knowledge on DC, especially in regards to the underlying molecular mechanisms toward the goal of developing useful diagnostic approaches and effective drugs based on these mechanisms. There exist several review articles which have focused on these points, but there still remains a lot to learn from published studies. In this review, the features, diagnosis and molecular mechanisms of DC are reviewed. Furthermore, potential therapeutic and prophylactic drugs are discussed.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2019) conducted a review in Diabetic cardiomyopathy. Diabetic cardiomyopathy is a major complication of diabetes characterized by functional and structural myocardial damage, with current treatments focusing on glycemic control and delaying heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: